Analyst Ami Fadia at Needham has elevated Neurocrine Biosciences (NBIX, Financial) from a Hold to a Buy rating, setting a price target of $138. This upgrade is driven by a favorable physician survey regarding the uptake of Crenessity in treating congenital adrenal hyperplasia.
Fadia indicates an increase in sales projections for Neurocrine, ranging from 8% to 10% above consensus forecasts for 2026 and the following years. This optimistic adjustment aligns with the belief that the recent decline in Neurocrine's stock performance, primarily due to concerns about Ingrezza's first-quarter dynamics, is overstated.
Moreover, despite fears regarding potential tariff impacts, the analyst remains confident in Neurocrine's ability to meet its 2025 targets. Fadia suggests that these external pressures are unlikely to significantly hinder the company's performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 22 analysts, the average target price for Neurocrine Biosciences Inc (NBIX, Financial) is $159.87 with a high estimate of $192.00 and a low estimate of $126.12. The average target implies an upside of 68.48% from the current price of $94.89. More detailed estimate data can be found on the Neurocrine Biosciences Inc (NBIX) Forecast page.
Based on the consensus recommendation from 26 brokerage firms, Neurocrine Biosciences Inc's (NBIX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Neurocrine Biosciences Inc (NBIX, Financial) in one year is $191.92, suggesting a upside of 102.26% from the current price of $94.89. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Neurocrine Biosciences Inc (NBIX) Summary page.
